CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −725 | $26.59 | $19K | 19,668 |
| 2025-08-19 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +16,666 | 16,666 | ||
| 2025-08-19 | Wilson Mark Andrew Chief Legal Officer | Sale | −676 | $26.59 | $18K | 20,312 |
| 2025-08-19 | Wilson Mark Andrew Chief Legal Officer | Grant or award · Stock Option | +21,666 | 21,666 | ||
| 2025-08-19 | ROBIN HOWARD W President & CEO | Sale | −1,573 | $26.59 | $42K | 69,340 |
| 2025-08-19 | ROBIN HOWARD W President & CEO | Grant or award · Stock Option | +86,666 | 86,666 | ||
| 2025-05-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −10,712 | $0.67 | $7K | 305,892 |
| 2025-05-19 | Wilson Mark Andrew Chief Legal Officer | Sale | −9,996 | $0.67 | $7K | 314,296 |
| 2025-05-19 | ROBIN HOWARD W President & CEO | Sale | −23,208 | $0.67 | $16K | 1,063,693 |
| 2025-02-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −10,300 | $1.01 | $10K | 316,604 |
| 2025-02-19 | Wilson Mark Andrew Chief Legal Officer | Sale | −11,040 | $1.01 | $11K | 324,292 |
| 2025-02-19 | ROBIN HOWARD W President & CEO | Sale | −23,774 | $1.01 | $24K | 1,086,901 |
| 2024-12-24 | Wilson Mark Andrew Chief Legal Officer | Sale | −16,560 | $0.89 | $15K | 335,332 |
| 2024-12-23 | Wilson Mark Andrew Chief Legal Officer | Sale | −33,402 | $0.90 | $30K | 351,892 |
| 2024-12-19 | Zalevsky Jonathan Chief R&D Officer | Sale | −51,115 | $0.94 | $48K | 326,904 |
| 2024-12-18 | ROBIN HOWARD W President & CEO | Sale | −85,035 | $0.99 | $84K | 1,110,675 |
| 2024-12-17 | ROBIN HOWARD W President & CEO | Sale | −46,995 | $1.01 | $47K | 1,195,710 |
| 2024-12-13 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +135,000 | 378,019 | ||
| 2024-12-13 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +270,000 | 270,000 | ||
| 2024-12-13 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +375,000 | 375,000 |
Page 4 of 18 · 355 trades